Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial.

A. M. Di Bisceglie, Paul Martin, C. Kassianides, M. Lisker-Melman, L. Murray, J. Waggoner, Z. Goodman, S. M. Banks, J. H. Hoofnagle

Research output: Contribution to journalArticle

1216 Citations (Scopus)

Abstract

Infection with the hepatitis C virus may result in chronic liver disease for which no effective therapy is now available. We studied the effects of recombinant human interferon alfa in a prospective, randomized, double-blind, placebo-controlled trial in patients with well-documented chronic hepatitis C. Forty-one patients were enrolled in the trial, 37 of whom were later found to have antibody to hepatitis C virus. Twenty-one patients received interferon alfa (2 million units) subcutaneously three times weekly for six months, and 20 received placebo. The mean serum aminotransferase levels and the histologic features of the liver improved significantly in the patients treated with interferon but not in the patients given placebo. Ten patients treated with interferon (48 percent) had a complete response, defined as a decline in mean serum aminotransferase levels to the normal range during therapy; three others had a decrease in mean aminotransferase levels of more than 50 percent. After treatment ended, however, serum aminotransferases usually returned to pretreatment levels; 6 to 12 months after the discontinuation of interferon therapy, only two patients (10 percent) still had normal values. We conclude that interferon alfa therapy is beneficial in reducing disease activity in chronic hepatitis C; however, the beneficial responses are often transient.

Original languageEnglish
Pages (from-to)1506-1510
Number of pages5
JournalNew England Journal of Medicine
Volume321
Issue number22
StatePublished - Nov 30 1989
Externally publishedYes

Fingerprint

Chronic Hepatitis C
Interferon-alpha
Placebos
Transaminases
Interferons
Therapeutics
Reference Values
Serum
Hepatitis C Antibodies
Hepacivirus
Liver Diseases
Chronic Disease
Liver
Infection

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Di Bisceglie, A. M., Martin, P., Kassianides, C., Lisker-Melman, M., Murray, L., Waggoner, J., ... Hoofnagle, J. H. (1989). Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. New England Journal of Medicine, 321(22), 1506-1510.

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. / Di Bisceglie, A. M.; Martin, Paul; Kassianides, C.; Lisker-Melman, M.; Murray, L.; Waggoner, J.; Goodman, Z.; Banks, S. M.; Hoofnagle, J. H.

In: New England Journal of Medicine, Vol. 321, No. 22, 30.11.1989, p. 1506-1510.

Research output: Contribution to journalArticle

Di Bisceglie, AM, Martin, P, Kassianides, C, Lisker-Melman, M, Murray, L, Waggoner, J, Goodman, Z, Banks, SM & Hoofnagle, JH 1989, 'Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial.', New England Journal of Medicine, vol. 321, no. 22, pp. 1506-1510.
Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. New England Journal of Medicine. 1989 Nov 30;321(22):1506-1510.
Di Bisceglie, A. M. ; Martin, Paul ; Kassianides, C. ; Lisker-Melman, M. ; Murray, L. ; Waggoner, J. ; Goodman, Z. ; Banks, S. M. ; Hoofnagle, J. H. / Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. In: New England Journal of Medicine. 1989 ; Vol. 321, No. 22. pp. 1506-1510.
@article{6d1882fa17304fccabc5b87f9175e746,
title = "Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial.",
abstract = "Infection with the hepatitis C virus may result in chronic liver disease for which no effective therapy is now available. We studied the effects of recombinant human interferon alfa in a prospective, randomized, double-blind, placebo-controlled trial in patients with well-documented chronic hepatitis C. Forty-one patients were enrolled in the trial, 37 of whom were later found to have antibody to hepatitis C virus. Twenty-one patients received interferon alfa (2 million units) subcutaneously three times weekly for six months, and 20 received placebo. The mean serum aminotransferase levels and the histologic features of the liver improved significantly in the patients treated with interferon but not in the patients given placebo. Ten patients treated with interferon (48 percent) had a complete response, defined as a decline in mean serum aminotransferase levels to the normal range during therapy; three others had a decrease in mean aminotransferase levels of more than 50 percent. After treatment ended, however, serum aminotransferases usually returned to pretreatment levels; 6 to 12 months after the discontinuation of interferon therapy, only two patients (10 percent) still had normal values. We conclude that interferon alfa therapy is beneficial in reducing disease activity in chronic hepatitis C; however, the beneficial responses are often transient.",
author = "{Di Bisceglie}, {A. M.} and Paul Martin and C. Kassianides and M. Lisker-Melman and L. Murray and J. Waggoner and Z. Goodman and Banks, {S. M.} and Hoofnagle, {J. H.}",
year = "1989",
month = "11",
day = "30",
language = "English",
volume = "321",
pages = "1506--1510",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "22",

}

TY - JOUR

T1 - Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial.

AU - Di Bisceglie, A. M.

AU - Martin, Paul

AU - Kassianides, C.

AU - Lisker-Melman, M.

AU - Murray, L.

AU - Waggoner, J.

AU - Goodman, Z.

AU - Banks, S. M.

AU - Hoofnagle, J. H.

PY - 1989/11/30

Y1 - 1989/11/30

N2 - Infection with the hepatitis C virus may result in chronic liver disease for which no effective therapy is now available. We studied the effects of recombinant human interferon alfa in a prospective, randomized, double-blind, placebo-controlled trial in patients with well-documented chronic hepatitis C. Forty-one patients were enrolled in the trial, 37 of whom were later found to have antibody to hepatitis C virus. Twenty-one patients received interferon alfa (2 million units) subcutaneously three times weekly for six months, and 20 received placebo. The mean serum aminotransferase levels and the histologic features of the liver improved significantly in the patients treated with interferon but not in the patients given placebo. Ten patients treated with interferon (48 percent) had a complete response, defined as a decline in mean serum aminotransferase levels to the normal range during therapy; three others had a decrease in mean aminotransferase levels of more than 50 percent. After treatment ended, however, serum aminotransferases usually returned to pretreatment levels; 6 to 12 months after the discontinuation of interferon therapy, only two patients (10 percent) still had normal values. We conclude that interferon alfa therapy is beneficial in reducing disease activity in chronic hepatitis C; however, the beneficial responses are often transient.

AB - Infection with the hepatitis C virus may result in chronic liver disease for which no effective therapy is now available. We studied the effects of recombinant human interferon alfa in a prospective, randomized, double-blind, placebo-controlled trial in patients with well-documented chronic hepatitis C. Forty-one patients were enrolled in the trial, 37 of whom were later found to have antibody to hepatitis C virus. Twenty-one patients received interferon alfa (2 million units) subcutaneously three times weekly for six months, and 20 received placebo. The mean serum aminotransferase levels and the histologic features of the liver improved significantly in the patients treated with interferon but not in the patients given placebo. Ten patients treated with interferon (48 percent) had a complete response, defined as a decline in mean serum aminotransferase levels to the normal range during therapy; three others had a decrease in mean aminotransferase levels of more than 50 percent. After treatment ended, however, serum aminotransferases usually returned to pretreatment levels; 6 to 12 months after the discontinuation of interferon therapy, only two patients (10 percent) still had normal values. We conclude that interferon alfa therapy is beneficial in reducing disease activity in chronic hepatitis C; however, the beneficial responses are often transient.

UR - http://www.scopus.com/inward/record.url?scp=0024981607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024981607&partnerID=8YFLogxK

M3 - Article

C2 - 2509917

AN - SCOPUS:0024981607

VL - 321

SP - 1506

EP - 1510

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 22

ER -